**This manuscript has been accepted for publication, but not yet copyedited or typeset, and may be subject to minor changes during the production process**
Latest Developments in Cellular Therapy for Multiple Myeloma
Abstract:
Overview
Novel drugs and continuous therapy have improved outcomes in patients with multiple myeloma (MM), however current therapies are largely non-curative with diminishing durations of response with subsequent therapies. Cellular therapies including chimeric antigen receptor (CAR) T cells have started to illustrate deeper and longer durations of relapse in the relapsed/refractory (RR) population. Current research seeks to expand on the durability of response, novel combinations and targets as well as the timing of CAR T in the treatment schema. This review summaries the updates in cellular therapy for MM.
Keywords
Multiple myeloma, chimeric antigen receptor T cells, BCMA
Article:
Article Information:
Disclosure
For all authors: Research Funding: all >10k
Tara K. Gregory’s institution receives research funds in her name from the following: Abbvie, Amgen, Acetylon, Bluebird, BMS, Celgene, Celularity, Constellation, CRISP Therapeutics, CURIS, EMD Sorono, Genentech, Glenmark, Janssen, Kesios, Lilly, Novartis, Poseida, Sanofi, Takeda, Teva, Vivolux
For Dr. Berdeja: Consultancy: all <10k
Institution received consultancy payments from the following: Amgen, BioClinica, BMS, Celgene, CRISPR Therapeutics, Janssen, Karyopharm, Kite Pharma, Legend, Prothena, SecuraBio, Servier, Takeda
Compliance With Ethics
This article involves a review of the MM CAR T cell therapy via a PUBMED literature review, recent presentations at medical conferences and ongoing research at ClinicalTrials.gov. It did not involve any studies with human or animal subjects performed by any of the authors.
Review Process
Double-blind peer review.
Authorship
The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.
Correspondence
Tara K Gregory, Sarah Cannon Research Institute, Denver, CO, USA.
E: tara.gregory@healthonecares.com
Support
No funding was received in the publication of this article.
Open Access
This article is freely accessible at touchONCOLOGY.com © Touch Medical Media 2020.
Received
2020-07-09
